JP2023520883A - Ｒｎａウイルス感染症、特にｃｏｖｉｄ－１９を処置するための抗ウイルス化合物および方法 - Google Patents

Ｒｎａウイルス感染症、特にｃｏｖｉｄ－１９を処置するための抗ウイルス化合物および方法 Download PDF

Info

Publication number
JP2023520883A
JP2023520883A JP2022560032A JP2022560032A JP2023520883A JP 2023520883 A JP2023520883 A JP 2023520883A JP 2022560032 A JP2022560032 A JP 2022560032A JP 2022560032 A JP2022560032 A JP 2022560032A JP 2023520883 A JP2023520883 A JP 2023520883A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
independently
ring
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520883A5 (https=
Inventor
スーン，タイ－セン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of JP2023520883A publication Critical patent/JP2023520883A/ja
Publication of JP2023520883A5 publication Critical patent/JP2023520883A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022560032A 2020-03-30 2021-03-18 Ｒｎａウイルス感染症、特にｃｏｖｉｄ－１９を処置するための抗ウイルス化合物および方法 Pending JP2023520883A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063001723P 2020-03-30 2020-03-30
US63/001,723 2020-03-30
US202063053908P 2020-07-20 2020-07-20
US63/053,908 2020-07-20
PCT/US2021/022976 WO2021202114A1 (en) 2020-03-30 2021-03-18 Antiviral compounds and method for treating rna viral infection, particularly covid-19

Publications (2)

Publication Number Publication Date
JP2023520883A true JP2023520883A (ja) 2023-05-22
JP2023520883A5 JP2023520883A5 (https=) 2024-03-25

Family

ID=77920792

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022560032A Pending JP2023520883A (ja) 2020-03-30 2021-03-18 Ｒｎａウイルス感染症、特にｃｏｖｉｄ－１９を処置するための抗ウイルス化合物および方法
JP2022560026A Pending JP2023520882A (ja) 2020-03-30 2021-03-18 肝臓指向性のウイルス感染症、特にｂ型肝炎およびｄ型肝炎を処置するための抗ウイルス化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022560026A Pending JP2023520882A (ja) 2020-03-30 2021-03-18 肝臓指向性のウイルス感染症、特にｂ型肝炎およびｄ型肝炎を処置するための抗ウイルス化合物および方法

Country Status (11)

Country Link
US (2) US20210308137A1 (https=)
EP (2) EP4126846A1 (https=)
JP (2) JP2023520883A (https=)
KR (2) KR20230004550A (https=)
CN (1) CN116075502B (https=)
AU (2) AU2021249224A1 (https=)
BR (2) BR112022019558A2 (https=)
CA (2) CA3179167A1 (https=)
IL (2) IL296927B2 (https=)
TW (2) TW202203914A (https=)
WO (2) WO2021202114A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102641010B1 (ko) 2023-12-04 2024-02-28 대한민국 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502651A (ja) * 2006-09-01 2010-01-28 サイリーン ファーマシューティカルズ インコーポレーティッド セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
JP2012524076A (ja) * 2009-04-17 2012-10-11 サイリーン ファーマシューティカルズ インコーポレーティッド プロテインキナーゼｃｋ２活性に関連する障害の治療方法
JP2013505252A (ja) * 2009-09-16 2013-02-14 サイリーン ファーマシューティカルズ インコーポレーティッド 三環式タンパク質キナーゼ調節剤
JP2013512903A (ja) * 2009-12-04 2013-04-18 サイリーン ファーマシューティカルズ インコーポレーティッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2016050203A1 (zh) * 2014-09-29 2016-04-07 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528704B (zh) * 2006-09-01 2014-04-09 生华生物科技股份有限公司 丝氨酸-苏氨酸蛋白激酶和parp调节剂
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
WO2021195126A1 (en) * 2020-03-24 2021-09-30 Burnet Michael W Anti-infective and anti-viral compounds and compositions
WO2021247367A1 (en) * 2020-06-02 2021-12-09 Yale University Compounds and compositions for treating, ameliorating, and/or preventing sars-cov-2 infection and/or complications thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502651A (ja) * 2006-09-01 2010-01-28 サイリーン ファーマシューティカルズ インコーポレーティッド セリン−トレオニンタンパク質キナーゼおよびｐａｒｐ調節因子
JP2011515337A (ja) * 2008-02-29 2011-05-19 サイレーン ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼモジュレーター
JP2012524076A (ja) * 2009-04-17 2012-10-11 サイリーン ファーマシューティカルズ インコーポレーティッド プロテインキナーゼｃｋ２活性に関連する障害の治療方法
JP2013505252A (ja) * 2009-09-16 2013-02-14 サイリーン ファーマシューティカルズ インコーポレーティッド 三環式タンパク質キナーゼ調節剤
JP2013512903A (ja) * 2009-12-04 2013-04-18 サイリーン ファーマシューティカルズ インコーポレーティッド Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物
WO2016050203A1 (zh) * 2014-09-29 2016-04-07 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID E. GORDON ET AL: ASARS-COV-2-HUMAN PROTEIN-PROTEIN INTERACTION MAP REVEALS DRUG TARGETS ANDPOT, BIORXIV, JPN6025006401, 27 March 2020 (2020-03-27), pages 1 - 45, ISSN: 0005671896 *

Also Published As

Publication number Publication date
CN116075502A (zh) 2023-05-05
EP4126846A1 (en) 2023-02-08
CA3179167A1 (en) 2021-10-07
AU2021249224A1 (en) 2022-12-01
IL296927B1 (en) 2025-07-01
US20210308110A1 (en) 2021-10-07
WO2021202114A1 (en) 2021-10-07
WO2021202115A1 (en) 2021-10-07
EP4126845A4 (en) 2024-05-01
US20210308137A1 (en) 2021-10-07
BR112022019554A2 (pt) 2022-12-06
CA3179372A1 (en) 2021-10-07
CN116075502B (zh) 2024-04-12
KR20230004550A (ko) 2023-01-06
JP2023520882A (ja) 2023-05-22
TW202203915A (zh) 2022-02-01
AU2021248867A1 (en) 2022-12-01
IL296924A (en) 2022-12-01
US11696911B2 (en) 2023-07-11
EP4126845A1 (en) 2023-02-08
KR20230004549A (ko) 2023-01-06
BR112022019558A2 (pt) 2022-12-06
IL296927B2 (en) 2025-11-01
IL296927A (en) 2022-12-01
TW202203914A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
RU2737190C2 (ru) Ингибиторы репликации вируса гриппа, способы их применения и использование
CN110437205B (zh) 吡啶烯基哌啶衍生物及其用途
CA3150316A1 (en) ERK5 DEGRADING AGENTS USED AS THERAPEUTIC AGENTS IN CANCER AND INFLAMMATORY DISEASES
CN115504968A (zh) 三嗪衍生物
US20250084091A1 (en) Inhibitors of sars-cov-2
BR112021000938A2 (pt) composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto
JP2023521237A (ja) 抗ウイルス１，３－ジ－オキソ－インデン化合物
CN116075502B (zh) 用于治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
WO2025247285A1 (zh) 一种可抑制il-17a的杂环化合物制备及其用途
CN112118891A (zh) 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物
HK40086507A (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
HK40086507B (zh) 用於治疗rna病毒(特别是covid-19)感染的抗病毒化合物及方法
CN114159445B (zh) 筛选抑制新型冠状病毒感染的小分子药物的方法及其应用
CN116761598A (zh) Fabp4调节化合物的抗病毒用途
CN114728006A (zh) 治疗冠状病毒感染的方法
US12138243B2 (en) Antiviral use of FABP4 modulating compounds
RU2407738C1 (ru) Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
JP7495758B2 (ja) マクロライド化合物及びその慢性呼吸器疾患の治療用途
JP2025533792A (ja) インダゾールピリドン化合物およびその用途
CN114539142A (zh) 吡啶酮类化合物，其药物组合物、制备方法和应用
KR20220017942A (ko) Pdl1 체크포인트 억제제로서의 헤테로고리 면역조절제
BR112017019758B1 (pt) Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv
NZ733805B2 (en) Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
BR122021002683B1 (pt) Tratamento combinado com um agonista de tlr7 e um inibidor de montagem de capsídeo de hbv

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826